Anúncio
Anúncio

LYRA

LYRA logo

Lyra Therapeutics, Inc. Common Stock

3.73
USD
Patrocinado
+0.12
+3.32%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

3.69

-0.04
-1.07%

Relatórios de Lucros LYRA

Rácio de surpresa positiva

LYRA separação 11 de 23 últimas estimativas.

48%

Próximo Relatório

Data do Próximo Relatório
11 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$199.58K
/
-$3.83
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+698.33%
/
+13.31%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
-4.51%
/
-52.13%

Lyra Therapeutics, Inc. Common Stock earnings per share and revenue

On 12 de nov. de 2025, LYRA reported earnings of -3.38 USD per share (EPS) for Q3 25, beating the estimate of -5.36 USD, resulting in a 36.94% surprise. Revenue reached 25.00 mil, compared to an expected 198.90 mil, with a -87.43% difference. The market reacted with a -1.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of -3.83 USD, with revenue projected to reach 199.58 mil USD, implying an aumentar of 13.31% EPS, and aumentar of 698.33% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Lyra Therapeutics, Inc. Common Stock reported EPS of -$3.38, beating estimates by 36.94%, and revenue of $25.00K, -87.43% below expectations.
The stock price moved down -1.55%, changed from $3.88 before the earnings release to $3.82 the day after.
The next earning report is scheduled for 11 de mar. de 2026.
Based on 6 analistas, Lyra Therapeutics, Inc. Common Stock is expected to report EPS of -$3.83 and revenue of $199.58K for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio